52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DEPEMOKIMAB COMPARED WITH MEPOLIZUMAB IN ADULTS WITH RELAPSING OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) RECEIVING STANDARD OF CARE (SOC) THERAPY

Registry ID

217102

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Start date

2023-05-05

Last update

2022-06-02

Conditions

• POLYANGITIS
• EOSINOPHILIC GRANULOMATOSIS

Related clinical trials

• A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NS-229 IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
• A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED 52-WEEK STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB COMPARED TO MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN PATIENTS RECEIVING STANDARD OF CARE THERAPY
• "ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF RELAPSING, NON-SEVERE, GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) (ABROGATE)."
• A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS IN SUBJECTS RECEIVING STANDARD OF CARE THERAPY

View on source registry